Interim Report 2019

Continued strong growth towards profitability Integumen (LSE: SKIN), the vertically integrated skin product test services company, today announces its interim [...]

Trading Update H1 2019

Strong H1 2019 Revenue Growth Continues Trading Update The positive results of major restructuring in H2 2018 has delivered accelerated [...]

Final Results 2018

Integumen (LSE: SKIN), today announces its final results for the year ended 31 December 2018. Highlights Total revenue £501k (including discontinued [...]

3 Labskin contracts with CBD

Integumen today announces that Labskin AI, the virtual laboratory platform, has entered into testing agreements with three new clients – [...]

Integumen Investor Event

Turner Pope Investor Evening Integumen is pleased to announce that Gerry Brandon, the Company’s CEO, will be presenting at an [...]

STOER For Men With CBD oil

Labskin CBD tests show greater than 99% reduction in bacterial growth on human skin Integumen plc (AIM: SKIN) is pleased [...]

Trading Update January 2019

Restructuring is Accelerating Growth into 2019 Trading Update The Company is pleased to announce the positive results of major restructuring [...]